Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…Abstract Number: 15L • 2017 ACR/ARHP Annual Meeting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Background/Purpose: CR845 is a selective kappa opioid receptor agonist with a peripheral mechanism of action. Here we report preliminary results from a Phase 2b study…Abstract Number: 13L • 2017 ACR/ARHP Annual Meeting
Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial
Background/Purpose: The current Phase 2 study was designed to evaluate safety, tolerability and preliminary efficacy of TPX-100 by IA administration in subjects with mild to…Abstract Number: 544 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
Background/Purpose: IRAK‑4 is a key node in innate immune signaling and is activated by the interleukin (IL)‑1 family receptors (IL‑1R, IL‑18R, and IL‑33R), in addition…Abstract Number: 583 • 2017 ACR/ARHP Annual Meeting
Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis
Background/Purpose: Metrology indices aimed as assessing spinal mobility in ankylosing spondylitis (AS) patients are used in clinical trials and clinical practice to assess disease severity…Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting
48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…Abstract Number: 1147 • 2017 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome or Acquired Hemophagocytic Lymphohistiocytosis in Adults: Demographics, Clinical Characteristics, and Survivorship in an American Academic Medical Center
Background/Purpose: Macrophage Activation Syndrome, also known as acquired Hemophagocytic Lymphohistiocytosis in adults, is an immune-mediated systemic inflammatory state. It is associated with multisystem organ failure…Abstract Number: 1661 • 2017 ACR/ARHP Annual Meeting
STAT4 Regulates Pathogenic IL-21 and IFN-γ in Tfh Cells in Murine and Human Lupus
Background/Purpose: Follicular helper T cells (Tfh) cells regulate the germinal center (GC) response by delivery of contact-dependent interactions and cytokines including IL-4, IFN-γ and IL-21.…Abstract Number: 1780 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Patients with Granulomatosis with Polyangiitis Requiring Hospitalization- a 10 Year Nationwide Analysis
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a form of systemic vasculitis with necrotizing granulomatous inflammation commonly involving upper and lower respiratory tracts, necrotizing glomerulonephritis and…Abstract Number: 1854 • 2017 ACR/ARHP Annual Meeting
Identifying Vulnerable Patient Populations Based on Age and Physical Function on Clinical Outcomes Following Total Knee Arthroplasty
Background/Purpose: : Total knee arthroplasty (TKA) has historically been viewed as a surgical procedure of last resort for older adults suffering with chronic arthritis. However,…Abstract Number: 2167 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Background/Purpose: Rituximab (RTX) in idiopathic inflammatory myopathies (IIM) failed to show efficacy in the placebo-controlled Rituximab in Myositis (RIM) trial. However, post hoc analyses indicated…Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…Abstract Number: 1321 • 2016 ACR/ARHP Annual Meeting
Distinguishing Features of Polymicrobial Septic Arthritis
Background/Purpose: Little is known about patients with polymicrobial septic arthritis (SA) and how they may differ from those with SA due to a single organism.…Abstract Number: 1362 • 2016 ACR/ARHP Annual Meeting
Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Background/Purpose: Previous studies have shown associations between reduced serum 25-hydroxyvitamin D (25OHD) levels, inflammation, and disease activity in pediatric systemic lupus erythematosus (pSLE). The goal…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »